Survival of an infant with massive fetomaternal hemorrhage with a neonatal hemoglobin concentration of 1.2 g/dL without evident neurodevelopmental sequelae

Jun Miyahara, Hiroshi Sugiura and Shigeru Ohki

Abstract
Fetomaternal hemorrhage is referred to as the passage of fetal blood into the maternal circulation. Massive hemorrhage can cause severe fetal anemia, affecting fetal and neonatal outcomes. A neonatal hemoglobin concentration (Hb), which is reportedly a significant prognostic factor, of <5.0 g/dL has been reported to carry a high risk of poor outcomes (death and major morbidity). We present a case of massive fetomaternal hemorrhage with the lowest value of neonatal Hb ever previously reported in a survivor, who subsequently met all the developmental milestones at the corrected age of 18 months. A male infant born at 27 weeks gestation, weighing 998 g, presented with severe anemia with an Hb of 1.2 g/dL and an HbF level in the mother’s blood of 2.4%, which led to a diagnosis of fetomaternal hemorrhage. Since there were no findings of hypovolemia, exchange transfusion was performed for prompt correction of the severe anemia without precipitating volume overload. The present case suggested that exchange transfusion might promptly correct anemia in patients with fetomaternal hemorrhage without hypovolemia without causing volume overload.

Keywords
Fetomaternal transfusion, fetomaternal hemorrhage, exchange transfusion

Case Report

A 23-year-old primigravida at 27 + 1 weeks gestation presented to her obstetrician with decreased fetal movements. FMH in small amounts occurs frequently, with less than 0.025 mL of fetal red cells present in 74% of postpartum conditions, and it is usually without any maternal or fetal signs. Using a common cutoff value of 30 mL for the diagnosis of FMH, incidence of FMH has been estimated at 3 in 1000 pregnancies. Massive hemorrhage might have devastating effects on the fetus, such as anemia, stillbirth, and neonatal death. Neonatal hemoglobin concentration (Hb) serves as one of the prognostic factors in such cases. A neonatal Hb value of 5.0 g/dL poses high risks of death and major morbidities. We present a case of massive FMH with the lowest ever reported value of neonatal Hb (1.2 g/dL) as compared to previous reports, who has met all the developmental milestones of his corrected age of 18 months.
ventilated. Apgar scores were 2 and 2 at 1 and 5 min, respectively. Umbilical cord pH and base deficit were 7.14 and 10.3, respectively. His laboratory blood tests indicated a hemoglobin concentration of 1.2 g/dL, hematocrit of 4.5%, and reticulocyte count of 25.9%. There was no visible bleeding or internal hemorrhage on abdominal/head ultrasonography. Both the mother’s and the neonate’s blood type was group A, RhD+, and the mother’s antibody screen was negative. There were no findings of congenital infection in the laboratory test. The histopathological examination of the placenta showed no indications of placental tumors or inflammation. The performance of the Kleihauer et al. test on the mother’s blood revealed the presence of 2.4% of fetal Hb (HbF), which was estimated as 986 mL of fetal blood loss (maternal hematocrit of 37%, newborn hematocrit of 4.5%, maternal HbF of 2.4%, assumed maternal blood volume of 5 L).

The neonate’s mean arterial blood pressure was 26 mmHg and heart rate was 162 bpm. Chest X-ray showed a cardiothoracic ratio (CTR) of 52% and echocardiogram showed a normal left ventricular end-diastolic dimension of 12.9 mm with normal fractional shortening of 25%, and no collapse of the inferior vena cava, all of which revealed the absence of hypovolemia. Therefore, we selected exchange transfusion for prompt correction of the severe anemia without causing volume overload. While waiting for the exchange transfusion, 16 mL of red blood cells was transfused over 2 h. Within 6 h after admission, after the exchange transfusion (total amount of 180 mL), the neonates Hb level had increased to 8.9 g/dL without any signs of volume overload. After successful weaning off mechanical ventilation and extubation on day 1, his clinical course remained stable. A magnetic resonance imaging (MRI) of Brain performed at 39 weeks of corrected age showed no findings suggestive of hypoxic ischemic brain injury, such as cystic changes or abnormal intensity in the white matter. Follow-up showed that the infant has met all the developmental milestones of his corrected age of 18 months.

**Discussion**

The present case suggests two clinical implications. The first is that it is possible for neonates with massive FMH with a neonatal Hb of as low as 1.2 g/dL to survive without evident neurodevelopmental sequelae. The Hb in the present patient was the lowest ever previously reported in survivors of FMH. The severity of FMH depends on the hemorrhagic volume and the rate of blood loss. Rubod et al. reported that when blood loss rate exceeds 40 mL/kg, the patients are at a high risk for stillbirth or severe morbidity, and when it exceeds 80 mL/kg, poor patient outcomes are inevitable. While waiting for the exchange transfusion, 16 mL of red blood cells was transfused over 2 h. Within 6 h after admission, after the exchange transfusion (total amount of 180 mL), the neonates Hb level had increased to 8.9 g/dL without any signs of volume overload. After successful weaning off mechanical ventilation and extubation on day 1, his clinical course remained stable. A magnetic resonance imaging (MRI) of Brain performed at 39 weeks of corrected age showed no findings suggestive of hypoxic ischemic brain injury, such as cystic changes or abnormal intensity in the white matter. Follow-up showed that the infant has met all the developmental milestones of his corrected age of 18 months.

The second implication of the present case is the usefulness of exchange transfusion for FMH without hypovolemia. Although a few reports have described exchange transfusion as the treatment for severe anemia due to FMH, only one report suggested the benefit of isovolumetric partial exchange transfusion for normovolemic FMH. The present case also suggested that exchange transfusion has the potential to promptly normalize Hb levels in normovolemic FMH patients without causing volume overload, thus preventing the occurrence of intraventricular hemorrhage.

**Conclusion**

In cases of FMH with severe anemia, it has been suggested that treatment should follow a tailor-made approach based on the patient’s cardiovascular status, which should be estimated by parameters such as vital signs, chest X-ray, and echocardiogram findings, so that simple rapid transfusion is selected for cases of FMH with hypovolemia, and exchange transfusion is selected for cases of FMH without hypovolemia.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.
Informed consent

Written, informed consent was obtained from the patient’s legally authorized representatives for anonymized patient information to be published in this article.

ORCID iD

Jun Miyahara https://orcid.org/0000-0001-8384-7183

References

1. Cunningham FG, Leveno KJ, Bloom SL, et al. *Williams obstetrics*. 23rd ed. New York: McGraw-Hill, 2010, pp. 617–618pp.
2. Sebring ES and Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence and clinical effects. *Transfusion* 1990; 30(4): 344–357.
3. Rubod C, Deruelle P, Le Goueff F, et al. Long-term prognosis for infants after massive fetomaternal hemorrhage. *Obstet Gynecol* 2007; 110(2 Pt 1): 256–260.
4. Wylie BJ and D’Alton ME. Fetomaternal hemorrhage. *Obstet Gynecol* 2010; 115(5): 1039–1051.
5. Kecskes Z. Large fetomaternal hemorrhage: clinical presentation and outcome. *J Matern Fetal Neonatal Med* 2003; 13(2): 128–132.
6. Christensen RD, Lambert DK, Baer VL, et al. Severe neonatal anemia from fetomaternal hemorrhage: report from a multi-hospital health-care system. *J Perinatol* 2013; 33(6): 429–434.
7. Kadooka M, Kato H, Kato A, et al. Effect of neonatal hemoglobin concentration on long-term outcome of infants affected by fetomaternal hemorrhage. *Early Hum Dev* 2014; 90(9): 431–434.
8. Kleihauer E, Braun H and Betke K. [Demonstration of fetal hemoglobin in erythrocytes of a blood smear]. *Klin Wochenschr* 1957; 35(12): 637–638.
9. Brace RA and Cheung CY. Fetal blood volume restoration following rapid fetal hemorrhage. *Am J Physiol* 1990; 259(2 Pt 2): H567–H573.
10. Brace RA. Mechanisms of fetal blood volume restoration after slow fetal hemorrhage. *Am J Physiol* 1989; 256(5 Pt 2): R1040–R1043.
11. Naulaers G, Barten S, Vanhole C, et al. Management of severe neonatal anemia due to fetomaternal transfusion. *Am J Perinatol* 1999; 16(4): 193–196.
12. Malcus P, Bjorklund LJ, Lilja M, et al. Massive feto-maternal hemorrhage: diagnosis by cardiotocography, Doppler ultrasonography and ST waveform analysis of fetal electrocardiography. *Fetal Diagn Ther* 2006; 21(1): 8–12.
13. Goldberg RN, Chung D, Goldman SL, et al. The association of rapid volume expansion and intraventricular hemorrhage in the preterm infant. *J Pediatr* 1980; 96(6): 1060–1063.